The Impact of Deep Brain Stimulation on Speech and Swallow Function in Parkinson Disease
NCT07026734
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Nearly one-million people in North America are now living with Parkinson's disease (PD), and that number is projected to rise to nearly 1.2 million by 2030. With advancements in neuromodulatory technologies, increasingly more of these individuals elect to undergo deep brain stimulation (DBS) surgery in order to control symptoms of the disease, including refractory tremor, medication-induced dyskinesias, and PD-associated dystonia. The two most common DBS neural targets for controlling these symptoms are the globus pallidus internal segment (GPi) and the subthalamic nucleus (STN).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Parkinson Disease, Idiopathic
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 45 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Florida
- Last updated on ClinicalTrials.gov
- July 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- University of Florida, Norman Fixel Institute for Neurological Diseases · Gainesville, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.